Roche’s diagnostic business sales offer a bright spot in Q4

treatments Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).

Roche cites COVID-19 and biosimilars in Q2 decline

Much of that decline can be attributed to increasing biosimilar competition to three of Roche’s key cancer therapies – Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).

Tecentriq misses the mark in advanced ovarian cancer

PD-L1 inhibitor failed to improved progression-free survival. Roche’s Genentech division has reported that Tecentriq, plus Avastin, was unable to improve progression-free survival as a front-line treatment ... The phase 3 IMagyn050 study evaluated the

AZ’s comeback drug cediranib stumbles in phase 3 trial

Cediranib has been developed as a potential oral alternative to drugs like Roche’s big-selling injectable VEGF inhibitor Avastin (bevacizumab), which is already used to treat ovarian cancer and other

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]